Close Menu

NEW YORK – Liquid biopsy firm Biocept on Monday priced a previously announced underwritten public offering of 24,600,000 shares of its common stock paired with warrants to purchase up to the same number of shares. 

Gross proceeds from the offering are expected to be about $10 million, which it will use to support ongoing operations and expansion of its business.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.